Stimulant Addiction Treatment: Cocaine, Meth, and Amphetamine Rehab

Stimulant addiction — encompassing cocaine, methamphetamine, and prescription amphetamines — represents one of the most clinically challenging categories of substance use disorder, distinguished by the absence of any FDA-approved pharmacotherapy for first-line treatment. This page covers the diagnostic criteria, evidence-based behavioral treatment frameworks, levels of care, and clinical decision points that define structured stimulant rehabilitation in the United States. Understanding these distinctions is essential for navigating the treatment landscape accurately, particularly given the significant overlap between stimulant use disorders and co-occurring psychiatric conditions.

Definition and Scope

Stimulant use disorder is classified under the broader substance use disorder framework established in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association. The DSM-5 specifies 11 diagnostic criteria — including craving, tolerance, withdrawal, and impaired social functioning — with severity rated as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria).

Three primary stimulant classes drive the majority of treatment admissions in the United States:

1. Cocaine and crack cocaine — short-acting dopamine reuptake inhibitors derived from coca leaf alkaloids
2. Methamphetamine — a long-acting synthetic catecholamine releaser with neurotoxic properties at high doses, classified as a Schedule II controlled substance under the Controlled Substances Act (21 U.S.C. § 812), as amended through December 23, 2024, including a technical correction to the statutory definitions
3. Prescription amphetamines — including amphetamine salts (Adderall) and lisdexamfetamine (Vyvanse), also Schedule II, where misuse or diversion leads to a clinical picture distinct from therapeutic use

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), methamphetamine-involved overdose deaths increased substantially between 2015 and 2021, with stimulants involved in approximately 32,537 overdose deaths in 2021 (CDC WONDER Database, 2022). For context on how stimulant disorders compare to other substance categories, see Opioid Addiction Treatment Options and Alcohol Rehab vs Drug Rehab.

How It Works

Stimulant addiction treatment follows a phase-based model aligned with the American Society of Addiction Medicine (ASAM) Criteria, which assigns patients to levels of care based on six dimensions: withdrawal potential, biomedical conditions, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment.

Because no FDA-approved medication exists specifically for stimulant use disorder (unlike opioid use disorder, where methadone and buprenorphine are available — see Medication-Assisted Treatment Overview), behavioral interventions form the clinical backbone of treatment.

The standard treatment sequence includes:

1. Medical evaluation and stabilization — Assessment for cardiovascular risk (cocaine and methamphetamine both carry acute cardiac risk), psychiatric comorbidities, and withdrawal symptoms including dysphoria, fatigue, hypersomnia, and anhedonia
2. Detoxification — Stimulant withdrawal is not typically life-threatening but produces significant psychological distress; Detox Services in Drug Rehab provides a full breakdown of supervised withdrawal protocols
3. Behavioral therapy engagement — Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) are the two modalities with the strongest evidence base for stimulant disorders, per NIST-referenced clinical guidelines via SAMHSA's Treatment Improvement Protocol (TIP) series
4. Level-of-care matching — Ranging from medically managed intensive inpatient (Inpatient Rehab Medical Services) to outpatient and intensive outpatient structures (Intensive Outpatient Programs)
5. Continuing care planning — Relapse prevention, peer support, and aftercare coordination

Contingency Management, which uses structured incentive systems (typically vouchers or prize-based rewards) to reinforce abstinence-confirmed by urine toxicology, has demonstrated the strongest empirical support for cocaine and methamphetamine specifically, with abstinence rates in CM-treated groups exceeding those of standard care by 20–30 percentage points in controlled trials cited in SAMHSA's TIP 42.

Common Scenarios

Stimulant treatment presentations vary substantially across the three drug classes and route of administration. Crack cocaine users frequently present with shorter use cycles but higher psychiatric comorbidity rates. Methamphetamine users — particularly those who smoke or inject — often present with more pronounced neurocognitive deficits, psychosis, and longer post-acute withdrawal syndromes lasting 4 to 8 weeks. Prescription amphetamine misuse frequently co-occurs with ADHD diagnoses, creating ambiguity in clinical assessment that requires structured evaluation per Substance Use Disorder Diagnosis criteria.

Co-occurring disorders are the norm rather than the exception in this population. Methamphetamine-induced psychosis can mimic schizophrenia spectrum disorders and requires differential diagnosis before treatment planning. Depression, anxiety, and PTSD are the three most frequently co-occurring psychiatric diagnoses in stimulant-using populations, per SAMHSA's 2022 National Survey on Drug Use and Health (NSDUH). For dual-diagnosis treatment framing, see Co-Occurring Disorders: Dual Diagnosis.

Treatment setting selection is also shaped by polysubstance use. Stimulant users who also use opioids or alcohol present with compounded medical risk and often require medically supervised settings during early stabilization.

Decision Boundaries

Not all stimulant use disorders require the same level of clinical intensity. ASAM criteria distinguish residential from outpatient placement primarily on the basis of:

• Severity of psychiatric symptoms — Active psychosis or suicidality requires a higher level of care
• Medical comorbidity — Cardiovascular compromise (arrhythmia, elevated troponin, hypertension) may require medical monitoring unavailable in standard outpatient settings
• Social and environmental stability — A recovery environment with high relapse exposure and low social support shifts placement toward residential care
• Prior treatment history — Repeated outpatient failures document a clinical rationale for Long-Term Residential Treatment or Partial Hospitalization Programs

Stimulant treatment also differs meaningfully from opioid treatment in the absence of a pharmacological maintenance pathway. There is no stimulant equivalent of methadone or buprenorphine. Research on potential pharmacotherapies — including bupropion, modafinil, and naltrexone combinations — remains under active investigation as of the NIDA research portfolio, but none carry FDA approval for stimulant use disorder as a primary indication.

Accreditation status and program standards are tracked by The Joint Commission and the Commission on Accreditation of Rehabilitation Facilities (CARF), both of which publish treatment standards applicable to stimulant-specific programming. For program verification, see Rehab Accreditation and Licensing.

References

• Substance Abuse and Mental Health Services Administration (SAMHSA) — National Survey on Drug Use and Health (NSDUH); Treatment Improvement Protocols (TIP series)
• National Institute on Drug Abuse (NIDA) — Stimulant medications research portfolio; clinical research on cocaine and methamphetamine treatment
• Centers for Disease Control and Prevention (CDC) WONDER Database — Overdose mortality data, stimulant-involved deaths
• Drug Enforcement Administration (DEA) — Controlled Substances Act Scheduling — Schedule II classification of cocaine, methamphetamine, and amphetamines; definitions amended December 23, 2024, including a technical correction to statutory definitions
• American Society of Addiction Medicine (ASAM) — ASAM Criteria — Six-dimensional level-of-care placement framework
• American Psychiatric Association — DSM-5 — Diagnostic criteria for stimulant use disorder
• SAMHSA TIP 42: Substance Abuse Treatment for Persons with Co-Occurring Disorders — Evidence base for Contingency Management and CBT